SCHEMBL4906595

SCHEMBL4906595

CC(C)(C)OC(=O)N(CC1CC1)C1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
CYP2C19 P33261 1/20 0.51
HSD11B1 P28845 1/20 0.50
HTT P42858 1/20 0.49
GRIN2B Q13224 8/20 0.47
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
CYP2D6 P10635 4/20 0.46
CYP2C9 P11712 4/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CYP3A4 P08684 3/20 0.44
STS P08842 1/20 0.44
GPR119 Q8TDV5 1/20 0.44
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
FAAH O00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1495946 0.96 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1
SCHEMBL30228841 0.94 HSD11B1 (0.58) SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1
SCHEMBL30492526 0.94 HSD11B1 (0.58) SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1
SCHEMBL30492423 0.94 HSD11B1 (0.58) SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1
SCHEMBL9008880 0.89 SMN1; SMN2 (0.55) SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1
SCHEMBL31714035 0.89 HSD11B1 (0.50) SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1
SCHEMBL31211181 0.88 HSD11B1 (0.46) SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1
SCHEMBL3252914 0.88 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1
SCHEMBL20660332 0.88 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1
SCHEMBL2827198 0.88 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024182778-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2024-09-06 WO disclosed
US-20080200460-A1 Chemical Compounds BROWN DEARG 2008-08-21 US disclosed
US-20080200460-A1 Chemical Compounds BROWN DEARG 2008-08-21 US disclosed
US-20080200460-A1 Chemical Compounds BROWN DEARG 2008-08-21 US disclosed
EP-1833792-A1 SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS CCR5 MODULATORS AstraZeneca AB (SE) 2007-09-19 EP disclosed
WO-2006067385-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200460-A1 Chemical Compounds CCR5, CXCR4, CXCR5 SMN1; SMN2 3791/4885NPC1 1430/4885RAB9A 3476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.